Elsevier

Clinica Chimica Acta

Volume 448, 25 August 2015, Pages 238-246
Clinica Chimica Acta

Invited critical review
MMPs and ADAMTSs in intervertebral disc degeneration

https://doi.org/10.1016/j.cca.2015.06.023Get rights and content

Highlights

  • IDD primarily results from loss of Col II and aggrecan within the discs.

  • MMPs and ADAMTSs aggravate IDD through degradation of disc Col II and aggrecan.

  • Inhibition of MMPs and ADAMTSs has enormous therapeutic potential for IDD.

Abstract

Intervertebral disc degeneration (IDD) is the most common diagnosis in patients with low back pain, a leading cause of musculoskeletal disability worldwide. The major components of extracellular matrix (ECM) within the discs are type II collagen (Col II) and aggrecan. Excessive destruction of ECM, especially loss of Col II and aggrecan, plays a critical role in promoting the occurrence and development of IDD. Matrix metalloproteinases (MMPs) and a disintegrin and metalloprotease with thrombospondin motifs (ADAMTSs) are primary enzymes that degrade collagens and aggrecan. There is a large and growing body of evidence that many members of MMPs and ADAMTSs are highly expressed in degenerative IVD tissue and cells, and are closely involved in ECM breakdown and the process of disc degeneration. In contrast, targeting these enzymes has shown promise for promoting ECM repair and mitigating disc regeneration. In the current review, after a brief description regarding the biology of MMPs and ADAMTSs, we mainly focus on their expression profiles, roles and therapeutic potential in IDD. A greater understanding of the catabolic pathways involved in IDD will help to develop potential prophylactic or regenerative biological treatment for degenerative disc disease in the future.

Introduction

Low back pain is a chronic, expensive, common medical problem in the world. It is the most common cause of disability in people younger than 45 years of age. Over 80% of adults will experience low back pain during their lifetimes [1]. At present, low back pain has become the second most frequent cause for visits to the hospital. There is growing evidence that the majority of low back pain is associated with intervertebral disc (IVD) degeneration (IDD) [2]. IDD constitutes the pathological foundation of most musculoskeletal disorders of the spine, including spinal stenosis, instability, disc herniation, radiculopathy and myelopathy. Despite the pathogenesis of IDD has not been completely understood, the predominant changes to IDD are characterized by in active cell number reduction, extracellular matrix (ECM) degradation, altered phenotype of normal disc cells, and presence of inflammation [3], [4]. Current treatment for IDD includes conservative management (bed rest, nonsteroidal anti-inflammatory drugs and physical therapy) and surgical procedures (laminectomy, corpectomy and fusion). If conservative treatment fails, then surgical fusion is commonly considered. All of these therapeutic methods are limited to treat the symptoms but do nothing to slow down or reverse the course of IDD. Thus, a greater understanding of IDD pathology is urgent to optimize treatment strategies and develop novel anti-IDD drugs.

The major ECM components within the discs are collagens and proteoglycans. In healthy discs, the rates of synthesis and breakdown of ECM are in equilibrium because of intricate regulation by growth factors and catabolic cytokines. When catabolism of ECM prevails over its anabolism, IDD often occurs. It is well established that loss of collagens and proteoglycans play a critical role in the development of disc degeneration [5]. Matrix metalloproteinases (MMPs) and a disintegrin and metalloprotease with thrombospondin motifs (ADAMTSs) are primary enzymes that cleave collagens and proteoglycans. It has been already reported that many members of MMPs and ADAMTSs are highly expressed in degenerative IVD tissue and cells, and these enzymes are deeply implicated in ECM breakdown and IDD progression [6]. Moreover, inactivation or knockdown of MMPs and ADAMTSs has shown enormous potential in promoting ECM repair and retarding disc regeneration [7]. In this review, we summarize the expression patterns and roles of MMPs and ADAMTSs in IDD, and describe recent progress regarding their inhibition as a promising biological therapeutic approach for disc degeneration.

Section snippets

Structure and function of IVDs

The IVD is an important component of the spinal column and forms a shock absorber between each vertebra, allowing bending, flexion and torsion of the spine. Normal IVD is a complicated structure that contains three morphologically distinct regions: nucleus pulposus (NP), annulus fibrosus (AF) and cartilaginous end plates. The cartilaginous end plates are localized to the cranial and caudal aspects of each disc and contain the peripheral vasculature that nourishes the disc [8].

As a thick, dense

Etiology of IDD

Although the exact pathophysiology of IDD has not been completely understood, the environmental and genetic factors are thought to be the main contributors to IDD. Occupational exposures such as vibration [14], mechanical influences including heavy lifting and weight [15], lifestyle factors such as lack of exercise [16], and the long use of non-Japanese cars [17] are known to promote IVD degeneration. Injuries associated with lifting or trauma [18], [19] and tobacco use [20], [21] have been

Matrix synthesis and degradation during disc degeneration

In healthy discs, the rates of synthesis and breakdown of the ECM are in equilibrium. When ECM breakdown prevails over its synthesis, IDD usually occurs. In the early stage of degeneration, collagen synthesis, in general, is increased. Especially, a clear increase in Col II content is seen within the NP, possibly signifying an attempted repair mechanism [7]. With more advanced degeneration, Col II content markedly decreases, resulting in a reduced ratio of Col II to Col I. Moreover, the

MMPs

MMPs, also called matrixins, are a very large family of calcium-dependent, zinc-containing endopeptidases. There are 24 MMP genes identified in humans to date, among which MMP-23 gene includes two genetic duplications. Thus, humans have 23 MMPs. MMPs are traditionally divided into six categories depending on their substrate specificity, protein structure and subcellular localization: collagenases, gelatinases, stromelysins, matrilysins (minimal domain), membrane-type MMPs, and unclassified

Disc MMP expression

MMP expression in normal IVD tissue is low and even devoid. In infant and preadolescent IVDs, MMP-1, MMP-2, MMP-3 and MMP-9 cannot be detected using immunohistochemistry; however, MMP-1 and MMP-3 appear in adult IVDs [35]. Le Maitre et al. have demonstrated that MMP-3 and MMP-13 expression is absent but a minimal expression of MMP-1 exists in non-degenerative discs [36]. In porcine discs, the level of MMP-1 mRNA increased with aging [37]. In contrast, the greatest expression of MMP-19 is

Roles of MMPs and ADAMTSs in IDD

The initiation and development of IDD is a multifactorial and complex process, and the involved mechanisms are not fully elucidated. The disruption of ECM is a major hallmark of disc degeneration. Given the key role of MMPs and ADAMTSs in ECM degradation, it is not surprising that these enzymes are involved in the pathology of IDD (Fig. 1). The effects of MMPs and ADAMTSs on IDD progression will be discussed in detail below. Simultaneously, agents that affect the course of IDD by regulating the

Therapeutic potential of targeting MMPs and ADAMTSs in IDD

Existing therapy options for IDD are restricted to treat the symptoms, and does not target its pathophysiology, highlighting the urgent need to develop biological therapeutic approaches. Since excessive ECM disruption is thought to the primary cause of IDD, delaying or stopping the characteristic ECM loss in disc degeneration has been suggested as a novel strategy which aims to restore matrix homeostasis by enhancing anabolism or reducing catabolism [99]. Considering the key role of MMPs and

Conclusions and future directions

It is clear that IDD primarily results from an imbalance between catabolism and anabolism of disc ECM components, especially Col II and aggrecan. As the primary mediators of Col II and aggrecan degradation, the majority of MMPs and ADAMTSs are highly expression in degenerative IVD tissue and cells, and play a crucial role in ECM breakdown and IDD progression. Despite the fact that inhibition of MMPs and ADAMTSs has shown efficacy and therapeutic potential in promoting ECM repair and preventing

Disclosure

The authors have declared no conflict of interest.

Acknowledgment

The authors gratefully acknowledge the financial support from the Natural Science Foundation in Hunan Province, China (2015JJ5003).

References (124)

  • H.E. Gruber et al.

    Matrix metalloproteinase-12 immunolocalization in the degenerating human intervertebral disc and sand rat spine: Biologic implications

    Exp. Mol. Pathol.

    (2014)
  • H.E. Gruber et al.

    Variations in aggrecan localization and gene expression patterns characterize increasing stages of human intervertebral disk degeneration

    Exp. Mol. Pathol.

    (2011)
  • S. Rajasekaran et al.

    Phenotype variations affect genetic association studies of degenerative disc disease: conclusions of analysis of genetic association of 58 single nucleotide polymorphisms with highly specific phenotypes for disc degeneration in 332 subjects

    Spine J.

    (2013)
  • J. Zhang et al.

    MicroRNAs in osteosarcoma

    Clin. Chim. Acta

    (2015)
  • S.X. Gu et al.

    MicroRNA-146a reduces IL-1 dependent inflammatory responses in the intervertebral disc

    Gene

    (2015)
  • C. Gendron et al.

    Proteolytic activities of human ADAMTS-5: comparative studies with ADAMTS-4

    J. Biol. Chem.

    (2007)
  • M.B. Ellman et al.

    Toll-like receptor adaptor signaling molecule MyD88 on intervertebral disk homeostasis: in vitro, ex vivo studies

    Gene

    (2012)
  • Z. Wang et al.

    Bone morphogenetic protein-7 antagonizes tumor necrosis factor-alpha-induced activation of nuclear factor kappaB and up-regulation of the ADAMTS, leading to decreased degradation of disc matrix macromolecules aggrecan and collagen II

    Spine J.

    (2014)
  • Y. Tian et al.

    Inflammatory cytokines associated with degenerative disc disease control aggrecanase-1 (ADAMTS-4) expression in nucleus pulposus cells through MAPK and NF-kappaB

    Am. J. Pathol.

    (2013)
  • J. Wang et al.

    TNF-alpha and IL-1beta promote a disintegrin-like and metalloprotease with thrombospondin type I motif-5-mediated aggrecan degradation through syndecan-4 in intervertebral disc

    J. Biol. Chem.

    (2011)
  • M.W. Lively

    Sports medicine approach to low back pain

    South. Med. J.

    (2002)
  • T. Kadow et al.

    Molecular basis of intervertebral disc degeneration and herniations: what are the important translational questions?

    Clin. Orthop. Relat. Res.

    (2014)
  • K.T. Weber et al.

    Developments in intervertebral disc disease research: pathophysiology, mechanobiology, and therapeutics

    Curr. Rev. Musculoskelet. Med.

    (2015)
  • M.V. Risbud et al.

    Role of cytokines in intervertebral disc degeneration: pain and disc content

    Nat. Rev. Rheumatol.

    (2014)
  • S.S. Sivan et al.

    Structure, function, aging and turnover of aggrecan in the intervertebral disc

    Biochim. Biophys. Acta

    (1840)
  • C.L. Le Maitre et al.

    Matrix synthesis and degradation in human intervertebral disc degeneration

    Biochem. Soc. Trans.

    (2007)
  • A.J. Freemont

    The cellular pathobiology of the degenerate intervertebral disc and discogenic back pain

    Rheumatology (Oxford)

    (2009)
  • M.V. Risbud et al.

    Toward an understanding of the role of notochordal cells in the adult intervertebral disc: from discord to accord

    Dev. Dyn.

    (2010)
  • S.Z. Wang et al.

    Cell and molecular biology of intervertebral disc degeneration: current understanding and implications for potential therapeutic strategies

    Cell Prolif.

    (2014)
  • S.Z. Wang et al.

    Enhancing intervertebral disc repair and regeneration through biology: platelet-rich plasma as an alternative strategy

    Arthritis Res. Ther.

    (2013)
  • I.M. Virtanen et al.

    Occupational and genetic risk factors associated with intervertebral disc disease

    Spine (Phila Pa 1976)

    (2007)
  • M.J. DePalma et al.

    Multivariable analyses of the relationships between age, gender, and body mass index and the source of chronic low back pain

    Pain Med.

    (2012)
  • A. Elfering et al.

    Risk factors for lumbar disc degeneration: a 5-year prospective MRI study in asymptomatic individuals

    Spine (Phila Pa 1976)

    (2002)
  • J.L. Kelsey et al.

    Acute prolapsed lumbar intervertebral disc. An epidemiologic study with special reference to driving automobiles and cigarette smoking

    Spine (Phila Pa 1976)

    (1984)
  • S.R. Schroeder et al.

    Risk factors for self-injury, aggression, and stereotyped behavior among young children at risk for intellectual and developmental disabilities

    Am. J. Intellect. Dev. Disabil.

    (2014)
  • P.C. Heyn et al.

    Mixed-reality exercise effects on participation of individuals with spinal cord injuries and developmental disabilities: a pilot study

    Top Spinal Cord Inj. Rehabil.

    (2014)
  • L. Cong et al.

    The interaction between aggrecan gene VNTR polymorphism and cigarette smoking in predicting incident symptomatic intervertebral disc degeneration

    Connect. Tissue Res.

    (2010)
  • M.C. Battie et al.

    Lumbar disc degeneration: epidemiology and genetic influences

    Spine (Phila Pa 1976)

    (2004)
  • T. Videman et al.

    Associations of 25 structural, degradative, and inflammatory candidate genes with lumbar disc desiccation, bulging, and height narrowing

    Arthritis Rheum.

    (2009)
  • C.F. Yao et al.

    Experimental study on lumbar intervetebral disc degeneration model with kidney deficiency by ovariectomizing

    Zhongguo Gu Shang

    (2013)
  • J.P. Urban et al.

    Degeneration of the intervertebral disc

    Arthritis Res. Ther.

    (2003)
  • N. Boos et al.

    Classification of age-related changes in lumbar intervertebral discs: 2002 Volvo Award in basic science

    Spine (Phila Pa 1976)

    (2002)
  • P.Y. Hwang et al.

    The role of extracellular matrix elasticity and composition in regulating the nucleus pulposus cell phenotype in the intervertebral disc: a narrative review

    J. Biomech. Eng.

    (2014)
  • T.P. Vacek et al.

    Matrix metalloproteinases in atherosclerosis: role of nitric oxide, hydrogen sulfide, homocysteine, and polymorphisms

    Vasc. Health Risk Manag.

    (2015)
  • S. Lemarchant et al.

    ADAMTS proteoglycanases in the physiological and pathological central nervous system

    J. Neuroinflammation

    (2013)
  • C. Weiler et al.

    2002 SSE Award Competition in Basic Science: expression of major matrix metalloproteinases is associated with intervertebral disc degradation and resorption

    Eur. Spine J.

    (2002)
  • C.L. Le Maitre et al.

    Localization of degradative enzymes and their inhibitors in the degenerate human intervertebral disc

    J. Pathol.

    (2004)
  • H. Cho et al.

    Snapshot of degenerative aging of porcine intervertebral disc: a model to unravel the molecular mechanisms

    Exp. Mol. Med.

    (2011)
  • H.E. Gruber et al.

    Immunolocalization of MMP-19 in the human intervertebral disc: implications for disc aging and degeneration

    Biotech. Histochem.

    (2005)
  • H. Xu et al.

    Correlation of matrix metalloproteinases-1 and tissue inhibitor of metalloproteinases-1 with patient age and grade of lumbar disk herniation

    Cell Biochem. Biophys.

    (2014)
  • Cited by (0)

    View full text